How is Setmelanotide (Imcivree) administered?
This describes how Setmelanotide (Imcivree) is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once daily schedule, generally over long-term in approved indications. Specific dosing is individual and beyond general information, and human evidence for Setmelanotide (Imcivree) is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once daily
- Cycle length: Long-term in approved indications
- Half-life: ~11 hours
References
- Setmelanotide for Obesity due to LEPR or POMC deficiency — Clément K et al., Lancet Diabetes Endocrinol, 2020
- Efficacy and safety of setmelanotide in patients with Bardet-Biedl syndrome and Alström syndrome: a phase 3 trial — Haqq AM et al., The Lancet Diabetes & Endocrinology, 2022
- Imcivree (setmelanotide) — Drugs@FDA approval record (ApplNo 213793) — FDA, Drugs@FDA
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Setmelanotide (Imcivree)
Full Setmelanotide (Imcivree) breakdownSetmelanotide (Imcivree) what it's used forSetmelanotide (Imcivree) side effectsSetmelanotide (Imcivree) mistakes to avoidSetmelanotide (Imcivree) who should avoid itSetmelanotide (Imcivree) half-lifeSetmelanotide (Imcivree) how long to workSetmelanotide (Imcivree) legal statusSetmelanotide (Imcivree) how it worksAsk the AI Coach
Last updated 2026-06-15.